Skip to main content

Table 2 Summary of MRI measures

From: Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

MRI measure

1 year

2 years

No. of new/newly enlarging T2 lesions

(n = 186)

(n = 157)

 Mean (SD)

0.98 (2.72)

0.45 (1.83)

 Median (min, max)

0 (0, 23)

0 (0, 11)

No. of Gd + lesions

(n = 191)

(n = 158)

 Mean (SD)

0.03 (0.24)

0.07 (0.39)

 Median (min, max)

0 (0, 3)

0 (0, 3)

 Mean change from baseline (95% CI)

−2.78 (−3.98, −1.58)

−2.78 (−4.18, − 1.37)

p-value

< 0.001

< 0.001

  1. CI confidence interval, Gd + gadolinium enhancing, MRI magnetic resonance imaging, SD standard deviation
  2. p-values are for change from baseline and are based on a Wilcoxon signed-rank test. Statistically significant p-values are shown in bold. p-values were not calculated for new/newly enlarging T2 lesions